ATE360659T1 - Synthese von nicht-peptidischen polymerderivaten mit hohem molekulargewicht - Google Patents

Synthese von nicht-peptidischen polymerderivaten mit hohem molekulargewicht

Info

Publication number
ATE360659T1
ATE360659T1 AT01994295T AT01994295T ATE360659T1 AT E360659 T1 ATE360659 T1 AT E360659T1 AT 01994295 T AT01994295 T AT 01994295T AT 01994295 T AT01994295 T AT 01994295T AT E360659 T1 ATE360659 T1 AT E360659T1
Authority
AT
Austria
Prior art keywords
molecular weight
high molecular
peptid
synthesis
weight non
Prior art date
Application number
AT01994295T
Other languages
English (en)
Inventor
Antoni Kozlowski
Xioaming Shen
Michael David Bentley
Zhihao Fang
Original Assignee
Nektar Therapeutics Al Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22973632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE360659(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nektar Therapeutics Al Corp filed Critical Nektar Therapeutics Al Corp
Application granted granted Critical
Publication of ATE360659T1 publication Critical patent/ATE360659T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polyethers (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Peptides Or Proteins (AREA)
AT01994295T 2000-12-18 2001-12-18 Synthese von nicht-peptidischen polymerderivaten mit hohem molekulargewicht ATE360659T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25680100P 2000-12-18 2000-12-18

Publications (1)

Publication Number Publication Date
ATE360659T1 true ATE360659T1 (de) 2007-05-15

Family

ID=22973632

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01994295T ATE360659T1 (de) 2000-12-18 2001-12-18 Synthese von nicht-peptidischen polymerderivaten mit hohem molekulargewicht

Country Status (12)

Country Link
US (1) US6774180B2 (de)
EP (1) EP1345982B1 (de)
JP (1) JP2004525212A (de)
KR (1) KR100807141B1 (de)
AT (1) ATE360659T1 (de)
AU (1) AU2002246705B2 (de)
CA (1) CA2431977C (de)
DE (1) DE60128135T2 (de)
ES (1) ES2284726T3 (de)
MX (1) MXPA03005460A (de)
TW (1) TW593427B (de)
WO (1) WO2002059179A2 (de)

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
KR100729977B1 (ko) * 1999-12-22 2007-06-20 넥타르 테라퓨틱스 에이엘, 코포레이션 폴리(에틸렌 글리콜)의 1-벤조트리아졸릴 카르보네이트에스테르의 제조 방법
US6602498B2 (en) * 2000-02-22 2003-08-05 Shearwater Corporation N-maleimidyl polymer derivatives
JP2003535208A (ja) 2000-06-08 2003-11-25 ラ ホヤ ファーマシューティカル カンパニー 高分子量ポリエチレン・オキシドを含む多価プラットホーム分子
US6436386B1 (en) * 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
EP1507755A4 (de) * 2001-12-11 2006-05-17 Sun Bio Inc Neue monofunktionelle polyethylengkykolaldehyde
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
SI3025726T1 (sl) 2002-01-18 2020-03-31 Biogen Ma Inc. Spojine polimera polialkilena in njihova uporaba
EP2311432B1 (de) 2002-06-07 2014-12-24 Dyax Corporation Polypeptides mit modifizierten Kunitz Domains und deren Verwendung zur Verringerung der Ischämie oder des Beginns einer systemischen Entzündungsreaktion verbunden mit einer chirurgischen Prozedur
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
AU2003254782A1 (en) * 2002-07-30 2004-04-30 Fujisawa Pharmaceutical Co., Ltd. Method of inhibiting nonspecific interaction between molecules on solid phase support
ES2897470T3 (es) 2002-09-09 2022-03-01 Nektar Therapeutics Alcanales poliméricos solubles en agua
WO2004060965A2 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
US7312301B2 (en) 2002-12-31 2007-12-25 Nektar Therapeutics Al, Corporation Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof
ATE485331T1 (de) 2003-01-06 2010-11-15 Nektar Therapeutics Thiolselektive wasserlösliche polymerderivate
LT1596887T (lt) 2003-02-26 2022-04-25 Nektar Therapeutics Polimero-faktoriaus viii fragmento konjugatai
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
ES2447423T3 (es) * 2003-08-29 2014-03-12 Dyax Corp. Inhibidores de proteasa poli-pegilados
US7790835B2 (en) * 2003-12-03 2010-09-07 Nektar Therapeutics Method of preparing maleimide functionalized polymers
NZ548256A (en) * 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
WO2006069220A2 (en) * 2004-12-22 2006-06-29 Ambrx, Inc. Modified human growth hormone
US7588745B2 (en) * 2004-04-13 2009-09-15 Si Options, Llc Silicon-containing products
US7632924B2 (en) * 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
MX2007000728A (es) * 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
US20060045866A1 (en) * 2004-09-01 2006-03-02 Chris Chappelow Novel high purity and high molecular weight mPEG alcohol compositions
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
KR101320936B1 (ko) 2004-12-21 2013-10-23 넥타르 테라퓨틱스 안정화된 중합체성 티올 시약
AU2005319518B2 (en) 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
KR101224781B1 (ko) 2004-12-22 2013-01-21 암브룩스, 인코포레이티드 비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
AU2005323106B2 (en) 2004-12-22 2010-07-29 Ambrx, Inc. Methods for expression and purification of recombinant human growth hormone
US7365127B2 (en) * 2005-02-04 2008-04-29 Enzon Pharmaceuticals, Inc. Process for the preparation of polymer conjugates
US8273339B2 (en) * 2005-04-12 2012-09-25 Nektar Therapeutics Polymer-based compositions and conjugates of antimicrobial agents
US20100135959A1 (en) 2005-06-03 2010-06-03 Ambrx, Inc. Human Interferon Molecules and Their Uses
EP1915412B1 (de) * 2005-07-19 2010-03-24 Nektar Therapeutics Verfahren zur herstellung von polymermaleimiden
EP1937824B1 (de) 2005-08-18 2013-03-13 Ambrx, Inc. trna-zusammensetzungen und deren verwendungen
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
JP2009514814A (ja) * 2005-10-21 2009-04-09 シナジェバ・バイオファーマ・コーポレイション グリコール化およびグリコシル化された家禽類由来の治療用たんぱく質
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
EP1986695B1 (de) 2006-02-21 2015-06-03 Nektar Therapeutics Segmentierte abbaubare polymere und daraus hergestellte konjugate
PT2064333E (pt) 2006-09-08 2014-06-09 Ambrx Inc Supressor híbrido arnt para células de vertebrados
EP2061878B1 (de) 2006-09-08 2014-01-08 Ambrx, Inc. Hybridunterdrücker-trna für wirbeltierzellen
CN106008699A (zh) * 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
HRP20120522T1 (hr) 2007-03-30 2012-08-31 Ambrx Modificirani fgf-21 polipeptidi i njihova uporaba
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
KR100958434B1 (ko) * 2007-05-29 2010-05-18 율촌화학 주식회사 사슬 말단 기능성화된 메톡시 폴리에틸렌글리콜 및 이를이용한 금속 나노입자
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
WO2009082817A1 (en) 2007-12-27 2009-07-09 Protiva Biotherapeutics, Inc. Silencing of polo-like kinase expression using interfering rna
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
PL2279254T3 (pl) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
EP2281041B1 (de) 2008-04-15 2014-07-02 Protiva Biotherapeutics Inc. Abdämpfen der csn5 genexpression unter verwendung von interferierender rns
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
MX2011003196A (es) 2008-09-26 2011-04-27 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
DK2342223T3 (en) 2008-09-26 2017-07-24 Ambrx Inc Modified animal erythropoietin polypeptides and their uses
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
CA2775092A1 (en) 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
KR20120123299A (ko) 2009-12-04 2012-11-08 제넨테크, 인크. 다중특이적 항체, 항체 유사체, 조성물 및 방법
EP2516455A4 (de) 2009-12-21 2013-05-22 Ambrx Inc Modifizierte schweine-somatotropin-polypeptide und deren verwendungen
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
EP3459564B1 (de) 2010-01-06 2021-10-27 Takeda Pharmaceutical Company Limited Plasmakallikreinbindende proteine
JP2013527856A (ja) 2010-05-12 2013-07-04 プロチバ バイオセラピューティクス インコーポレイティッド 陽イオン性脂質およびその使用方法
WO2011141704A1 (en) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Novel cyclic cationic lipids and methods of use
CA2798518A1 (en) 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
PH12013500241A1 (en) 2010-08-17 2013-03-11 Ambrx Inc Modified relaxin polypeptides and their uses
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
PT2817287T (pt) 2012-02-24 2018-12-28 Arbutus Biopharma Corp Lípidos catiónicos trialquílicos e seus métodos de utilização
HUE043552T2 (hu) 2012-06-08 2019-09-30 Sutro Biopharma Inc Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
EP2863955B1 (de) 2012-06-26 2016-11-23 Sutro Biopharma, Inc. Modifizierte fc-proteine mit nichtnatürlichen ortsspezifische aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
US9682934B2 (en) 2012-08-31 2017-06-20 Sutro Biopharma, Inc. Modified amino acids
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
CA2919226C (en) 2013-07-23 2024-05-14 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
AU2015235967B2 (en) 2014-03-27 2020-10-22 Takeda Pharmaceutical Company Limited Compositions and methods for treatment of diabetic macular edema
AU2015328012A1 (en) 2014-10-02 2017-05-11 Arbutus Biopharma Corporation Compositions and methods for silencing Hepatitis B virus gene expression
SMT202100388T1 (it) 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
US10046058B2 (en) 2014-12-02 2018-08-14 Rezolute, Inc. Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates
WO2016197132A1 (en) 2015-06-04 2016-12-08 Protiva Biotherapeutics Inc. Treating hepatitis b virus infection using crispr
KR20180015131A (ko) 2015-06-04 2018-02-12 안트리아바이오 인크. 부위-특이적 단백질 콘쥬게이트의 제조를 위한 아민 페길화 방법
US10626393B2 (en) 2015-06-04 2020-04-21 Arbutus Biopharma Corporation Delivering CRISPR therapeutics with lipid nanoparticles
CN108350455A (zh) 2015-07-29 2018-07-31 阿布特斯生物制药公司 用于使b型肝炎病毒基因表达沉默的组合物和方法
EP3340967B1 (de) 2015-08-24 2024-05-22 Halo-Bio Rnai Therapeutics, Inc. Polynukleotid-nanopartikel zur modulation der genexpression und verwendungen davon
JP7003354B2 (ja) 2015-12-11 2022-03-04 武田薬品工業株式会社 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
MX2018016389A (es) 2016-06-30 2019-08-16 Arbutus Biopharma Corp Composiciones y metodos para suministro de arn mensajero.
EP3500294A4 (de) 2016-08-22 2020-07-29 Arbutus Biopharma Corporation Anti-pd-1-antikörper oder fragmente davon zur behandlung von hepatitis b
US10266578B2 (en) 2017-02-08 2019-04-23 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
EP3849614B1 (de) 2018-09-11 2023-12-20 Ambrx, Inc. Interleukin-2-polypeptidkonjugate und deren verwendungen
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
CA3128081A1 (en) 2019-02-12 2020-08-20 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
US10882954B2 (en) 2019-04-11 2021-01-05 Sunbio Inc. Tertiary alkoxy polyethylene glycol and derivatives thereof
JP2023510854A (ja) 2020-01-13 2023-03-15 武田薬品工業株式会社 小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用
IL296099A (en) 2020-03-11 2022-11-01 Ambrx Inc Interleukin-2 polypeptide conjugates and methods of using them
EP4121018A4 (de) 2020-03-17 2024-07-03 Genevant Sciences Gmbh Kationische lipide zur lipidnanopartikelabgabe von therapeutika an hepatische stellatzellen
WO2021216572A1 (en) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
US20230302150A1 (en) 2020-08-20 2023-09-28 Ambrx, Inc. Antibody-tlr agonist conjugates, methods and uses thereof
US11952461B2 (en) 2021-03-22 2024-04-09 Sunbio, Inc. Siloxy polyethylene glycol and derivatives thereof
CA3213805A1 (en) 2021-04-03 2022-10-06 Feng Tian Anti-her2 antibody-drug conjugates and uses thereof
US20250332112A1 (en) 2022-01-31 2025-10-30 Genevant Sciences Gmbh Ionizable cationic lipids for lipid nanoparticles
EP4692166A1 (de) * 2023-03-28 2026-02-11 NOF Corporation Verfahren zur herstellung eines aktivierten polyethylenglykolderivats
WO2025052278A1 (en) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2025133951A1 (en) 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles
WO2025210521A1 (en) 2024-04-04 2025-10-09 Genevant Sciences Gmbh Lipid nanoparticles for stimulating t cells
WO2025210520A1 (en) 2024-04-04 2025-10-09 Genevant Sciences Gmbh Lipid nanoparticles for inducing an immunological response
WO2026022656A2 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Lipid particle formulations with permanently charged cationic lipids
WO2026022677A1 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Permanently charged cationic lipids
JP2026027206A (ja) * 2024-08-05 2026-02-18 日油株式会社 末端に活性基を有する活性化ポリエチレングリコールの製造方法および末端に活性基を有する活性化ポリエチレングリコール
WO2026043823A2 (en) 2024-08-19 2026-02-26 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0206448B1 (de) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6362254B2 (en) 1998-03-12 2002-03-26 Shearwater Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
AU781336B2 (en) * 1999-10-08 2005-05-19 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom

Also Published As

Publication number Publication date
US6774180B2 (en) 2004-08-10
WO2002059179A2 (en) 2002-08-01
CA2431977A1 (en) 2002-08-01
WO2002059179A3 (en) 2002-10-03
CA2431977C (en) 2011-09-06
DE60128135T2 (de) 2008-01-03
EP1345982B1 (de) 2007-04-25
US20020082345A1 (en) 2002-06-27
KR100807141B1 (ko) 2008-02-27
AU2002246705B2 (en) 2006-01-19
ES2284726T3 (es) 2007-11-16
KR20030068178A (ko) 2003-08-19
DE60128135D1 (de) 2007-06-06
JP2004525212A (ja) 2004-08-19
EP1345982A2 (de) 2003-09-24
MXPA03005460A (es) 2004-10-14
TW593427B (en) 2004-06-21

Similar Documents

Publication Publication Date Title
ATE360659T1 (de) Synthese von nicht-peptidischen polymerderivaten mit hohem molekulargewicht
MXPA06012583A (es) Nanoparticulas pegiladas.
NO20055849L (no) Nye polyetylenglykolmodifiserte forbindelser og anvendelse av slike
KR910009711A (ko) 헤테로원자-함유 트리사이클릭 화합물
DE60304992D1 (de) Supramolekularpolymere
DE60017831D1 (de) Dermale zusammensetzungen
IT1303735B1 (it) Acidi ialuronici reticolati e loro usi medici.
DE60135285D1 (de) Diester-derivate der phthalsäure und elektronendonatoren
DE69701447D1 (de) Olefinpolymerisationskatalysatoren, dessen herstellung und verwendung
ATE221089T1 (de) Michael-additionspolymer mit endständiger silan- gruppe
ATE509940T1 (de) Massiv parallele synthese biopolymerer arrays
ATE464339T1 (de) Kern-schale tectodendrimere
BR9105000A (pt) Composicao de peso molecular modificado,composicao,composicao a base de solvente organico,a base de agua e curavel,produto e artigo
WO2010115080A3 (en) Self-assembling peptides bearing organic electronic functionality and applications employing the same
WO2007016380A3 (en) Cyclitol linker polymer conjugate
Okoth et al. End-labeled amino terminated monotelechelic glycopolymers generated by ROMP and Cu (I)-catalyzed azide–alkyne cycloaddition
WO2001049941A3 (en) Light stable fluorescent vinyl suitable for use as a highway retroreflective roll-up sign
AU2003218046A1 (en) Method for copolyestercarbonate synthesis
MXPA05007371A (es) Sistema de polituneles.
ATE458770T1 (de) Polymere, ihre herstellung und verwendungen
EP1220851A4 (de) Verbindungen die kohlenstoff-dioxid-philie zeigen und verfahren zu ihrer herstellung
DE60112946D1 (de) Harzzusammensetzung
BR9810210A (pt) Melhoramentos em ou referentes a composiçõespoliméricas
EP1394153A4 (de) Derivate von thiolverbindungen, härtende zusammensetzungen, die diese derivate enthalten, und daraus geformte artikel
WO2001014453A8 (en) Copolycarbonate preparation by solid state polymerization

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties